172 related articles for article (PubMed ID: 37896899)
41. Variants in microRNA genes in familial papillary thyroid carcinoma.
Tomsic J; Fultz R; Liyanarachchi S; Genutis LK; Wang Y; Li W; Volinia S; Jazdzewski K; He H; Wakely PE; Senter L; de la Chapelle A
Oncotarget; 2017 Jan; 8(4):6475-6482. PubMed ID: 28031538
[TBL] [Abstract][Full Text] [Related]
42. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
43. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer.
Xiong Y; Zhang L; Holloway AK; Wu X; Su L; Kebebew E
PLoS One; 2011; 6(10):e24717. PubMed ID: 21998631
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Huang Y; Yu S; Cao S; Yin Y; Hong S; Guan H; Li Y; Xiao H
Thyroid; 2018 Sep; 28(9):1162-1173. PubMed ID: 29882471
[TBL] [Abstract][Full Text] [Related]
45. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
47. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
48. LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145.
Lei H; Gao Y; Xu X
Acta Biochim Biophys Sin (Shanghai); 2017 Jul; 49(7):588-597. PubMed ID: 28645161
[TBL] [Abstract][Full Text] [Related]
49. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential.
Bozec A; Lassalle S; Hofman V; Ilie M; Santini J; Hofman P
Curr Med Chem; 2010; 17(30):3449-61. PubMed ID: 20738253
[TBL] [Abstract][Full Text] [Related]
50. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
51. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a.
Yan DG; Liu N; Chao M; Tu YY; Liu WS
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1134-1144. PubMed ID: 30779082
[TBL] [Abstract][Full Text] [Related]
52. Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p.
Fu S; Zhao N; Jing G; Yang X; Liu J; Zhen D; Tang X
Biomed Pharmacother; 2020 Aug; 128():110327. PubMed ID: 32505823
[TBL] [Abstract][Full Text] [Related]
53. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
54. MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.
Liu L; Wang J; Li X; Ma J; Shi C; Zhu H; Xi Q; Zhang J; Zhao X; Gu M
Biochem Biophys Res Commun; 2015 Feb; 457(4):621-6. PubMed ID: 25603050
[TBL] [Abstract][Full Text] [Related]
55. MiR-192-5p inhibits proliferation, migration, and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3.
Fu S; Ma C; Tang X; Ma X; Jing G; Zhao N; Ran J
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34486645
[TBL] [Abstract][Full Text] [Related]
56. LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
Yuan Q; Liu Y; Fan Y; Liu Z; Wang X; Jia M; Geng Z; Zhang J; Lu X
Int J Biochem Cell Biol; 2018 May; 98():1-9. PubMed ID: 29474928
[TBL] [Abstract][Full Text] [Related]
57. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
Wang Z; Zhang H; Zhang P; Dong W; He L
Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
[TBL] [Abstract][Full Text] [Related]
59. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
60. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
